The cardiac protection research of Intensive statin for percutaneous coronary intervention
Author(s): CHEN Hui, MA Lei, YU Shu-hua
Pages: 39-41
Year: 2015 Issue: 7
Journal: Chinese Journal for Clinicians
Keyword: Statin; Pleiotropic; Percutaneous coronary intervention; Cardiac muscle; Security;
Abstract: Objective Explore acute coronary syndrome patients who suffer elective percutaneous coronary interven-tion treatment with preoperative given intensive atorvastatin to study its protective effect on the heart. Method The 68 patients, in heart line of our hospital from January 2012 to December 2012, suffer elective PCI with acute coro-nary syndrome. Patients were divided into strengthening group and control group, 34 patients in each group. Pa-tients in strengthening have orally atorvastatin 20 mg a day on the basis of preoperative six to eight hours and take atorvastatin 80 mg. Patients take atorvastatin 40 mg a day for 30days and take atorvastatin 20mg a day continuded. The control group take orally atorvastatin 20mg a day,and exsanguinate assay High-sensitivity C –reactive protein ( hs-CRP) , phosphocreatine ( CKMB ) and cardiac troponin I at preoperative and postoperative 24 hours. After a week, they need to exsanguinate assay liver enzyme and myocardial enzyme spectrum, and check PCI postoperative follow-up 30 days, heart blood vessel of adverse events at the same time. Result After 24 hours the strengthening group and control group, the hs CRP, CKMB and cTnI compared with preoperative condition both elevated signifi-cantly. Patients in strengthening group, preoperative and postoperative 24 hours of the hs CRP, CKMB and cTnI are dropped significantly. strengthening group has adverse cardiovascular events no case 30 days and control group had 2 cases. There are significant difference. Conclusion Acute coronary syndrome patients undergo elective PCI post-operative inflammatory factor increasing. Elective PCI preoperative given atorvastatin 80 mg suit can probably reduce the level of inflammatory factors and cardial enzymes, reduce myocardial injured, and reduce major cardiovascular adverse events within 30 days, and no serious adverse reactions.
Pages: 39-41
Year: 2015 Issue: 7
Journal: Chinese Journal for Clinicians
Keyword: Statin; Pleiotropic; Percutaneous coronary intervention; Cardiac muscle; Security;
Abstract: Objective Explore acute coronary syndrome patients who suffer elective percutaneous coronary interven-tion treatment with preoperative given intensive atorvastatin to study its protective effect on the heart. Method The 68 patients, in heart line of our hospital from January 2012 to December 2012, suffer elective PCI with acute coro-nary syndrome. Patients were divided into strengthening group and control group, 34 patients in each group. Pa-tients in strengthening have orally atorvastatin 20 mg a day on the basis of preoperative six to eight hours and take atorvastatin 80 mg. Patients take atorvastatin 40 mg a day for 30days and take atorvastatin 20mg a day continuded. The control group take orally atorvastatin 20mg a day,and exsanguinate assay High-sensitivity C –reactive protein ( hs-CRP) , phosphocreatine ( CKMB ) and cardiac troponin I at preoperative and postoperative 24 hours. After a week, they need to exsanguinate assay liver enzyme and myocardial enzyme spectrum, and check PCI postoperative follow-up 30 days, heart blood vessel of adverse events at the same time. Result After 24 hours the strengthening group and control group, the hs CRP, CKMB and cTnI compared with preoperative condition both elevated signifi-cantly. Patients in strengthening group, preoperative and postoperative 24 hours of the hs CRP, CKMB and cTnI are dropped significantly. strengthening group has adverse cardiovascular events no case 30 days and control group had 2 cases. There are significant difference. Conclusion Acute coronary syndrome patients undergo elective PCI post-operative inflammatory factor increasing. Elective PCI preoperative given atorvastatin 80 mg suit can probably reduce the level of inflammatory factors and cardial enzymes, reduce myocardial injured, and reduce major cardiovascular adverse events within 30 days, and no serious adverse reactions.
Related Articles